Human UDP-glucuronosyltransferase UGT2A2: CDNA construction, expression, and functional characterization in comparison with UGT2A1 and UGT2A3

Nina Sneitz, Michael H. Court, Xiuling Zhang, Kaisa Laajanen, Karen K. Yee, Pamela Dalton, Xinxin Ding, Moshe Finel

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

OBJECTIVES: Characterize the expression and glucuronidation activities of the human uridine 5′-diphospho (UDP)-glucuronosyltransferase (UGT) 2A2. METHOD: UGT2A1 was cloned from nasal mucosa mRNA. Synthetic cDNA for UGT2A2 was constructed assuming exon sharing between UGT2A1 and UGT2A2 (Mackenzie et al., Pharmacogenetics and Genomics 2005, 15:677-685). Exon 1 of UGT2A2 was amplified from genomic DNA and combined with exons 2-6 of UGT2A1. UGT2A3 was cloned from liver mRNA. Quantitative reverse-transcribed-PCR (RT-PCR) was used to evaluate the expression of all the three UGTs of subfamily 2A in different tissues. Recombinant UGT2A1, UGT2A2 and UGT2A3 were expressed in baculovirus-infected insect cells and analyzed for glucuronidation activity towards different substrates. RESULTS: DNA sequencing of RT-PCR products from human nasal mucosa mRNA, confirmed exon sharing between UGT2A1 and UGT2A2. In addition, it indicated that the N-terminal signal peptide sequence of UGT2A2 is the longest among the human UGTs. Quantitative RT-PCR revealed that both UGT2A1 and UGT2A2 are mainly expressed in the nasal mucosa, and that their expression level in fetal samples was much higher than in adults. Activity assays with recombinant UGTs 2A1-2A3 showed broad substrate selectivity for UGT2A1 and UGT2A2. Although glucuronidation rates and substrate affinities were mostly higher in UGT2A1, the Km values for UDP-glucuronic acid were similar in both UGTs. In addition, there were regioselectivity differences between the two UGTs and, with a few substrates, particularly ethinylestradiol, the activity of UGT2A2 was higher. CONCLUSION: UGT2A2 is mainly expressed in the nasal mucosa and it has glucuronidation activity towards several different endobiotic and xenobiotic substrates.

Original languageEnglish (US)
Pages (from-to)923-934
Number of pages12
JournalPharmacogenetics and Genomics
Volume19
Issue number12
DOIs
StatePublished - Dec 1 2009
Externally publishedYes

Fingerprint

Glucuronosyltransferase
Nasal Mucosa
Uridine
Exons
Polymerase Chain Reaction
Messenger RNA
Glucuronic Acid
Ethinyl Estradiol
Baculoviridae
Pharmacogenetics
Xenobiotics
Protein Sorting Signals
Genomics
DNA Sequence Analysis
Human Activities
Insects
Complementary DNA
Liver
DNA

Keywords

  • Glucuronidation
  • Nasal mucosa mRNA
  • Subfamily UGT2A

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Genetics(clinical)

Cite this

Human UDP-glucuronosyltransferase UGT2A2 : CDNA construction, expression, and functional characterization in comparison with UGT2A1 and UGT2A3. / Sneitz, Nina; Court, Michael H.; Zhang, Xiuling; Laajanen, Kaisa; Yee, Karen K.; Dalton, Pamela; Ding, Xinxin; Finel, Moshe.

In: Pharmacogenetics and Genomics, Vol. 19, No. 12, 01.12.2009, p. 923-934.

Research output: Contribution to journalArticle

Sneitz, Nina ; Court, Michael H. ; Zhang, Xiuling ; Laajanen, Kaisa ; Yee, Karen K. ; Dalton, Pamela ; Ding, Xinxin ; Finel, Moshe. / Human UDP-glucuronosyltransferase UGT2A2 : CDNA construction, expression, and functional characterization in comparison with UGT2A1 and UGT2A3. In: Pharmacogenetics and Genomics. 2009 ; Vol. 19, No. 12. pp. 923-934.
@article{05a698c7743245bfbf604c28961b4f29,
title = "Human UDP-glucuronosyltransferase UGT2A2: CDNA construction, expression, and functional characterization in comparison with UGT2A1 and UGT2A3",
abstract = "OBJECTIVES: Characterize the expression and glucuronidation activities of the human uridine 5′-diphospho (UDP)-glucuronosyltransferase (UGT) 2A2. METHOD: UGT2A1 was cloned from nasal mucosa mRNA. Synthetic cDNA for UGT2A2 was constructed assuming exon sharing between UGT2A1 and UGT2A2 (Mackenzie et al., Pharmacogenetics and Genomics 2005, 15:677-685). Exon 1 of UGT2A2 was amplified from genomic DNA and combined with exons 2-6 of UGT2A1. UGT2A3 was cloned from liver mRNA. Quantitative reverse-transcribed-PCR (RT-PCR) was used to evaluate the expression of all the three UGTs of subfamily 2A in different tissues. Recombinant UGT2A1, UGT2A2 and UGT2A3 were expressed in baculovirus-infected insect cells and analyzed for glucuronidation activity towards different substrates. RESULTS: DNA sequencing of RT-PCR products from human nasal mucosa mRNA, confirmed exon sharing between UGT2A1 and UGT2A2. In addition, it indicated that the N-terminal signal peptide sequence of UGT2A2 is the longest among the human UGTs. Quantitative RT-PCR revealed that both UGT2A1 and UGT2A2 are mainly expressed in the nasal mucosa, and that their expression level in fetal samples was much higher than in adults. Activity assays with recombinant UGTs 2A1-2A3 showed broad substrate selectivity for UGT2A1 and UGT2A2. Although glucuronidation rates and substrate affinities were mostly higher in UGT2A1, the Km values for UDP-glucuronic acid were similar in both UGTs. In addition, there were regioselectivity differences between the two UGTs and, with a few substrates, particularly ethinylestradiol, the activity of UGT2A2 was higher. CONCLUSION: UGT2A2 is mainly expressed in the nasal mucosa and it has glucuronidation activity towards several different endobiotic and xenobiotic substrates.",
keywords = "Glucuronidation, Nasal mucosa mRNA, Subfamily UGT2A",
author = "Nina Sneitz and Court, {Michael H.} and Xiuling Zhang and Kaisa Laajanen and Yee, {Karen K.} and Pamela Dalton and Xinxin Ding and Moshe Finel",
year = "2009",
month = "12",
day = "1",
doi = "10.1097/FPC.0b013e3283330767",
language = "English (US)",
volume = "19",
pages = "923--934",
journal = "Pharmacogenetics and Genomics",
issn = "1744-6872",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Human UDP-glucuronosyltransferase UGT2A2

T2 - CDNA construction, expression, and functional characterization in comparison with UGT2A1 and UGT2A3

AU - Sneitz, Nina

AU - Court, Michael H.

AU - Zhang, Xiuling

AU - Laajanen, Kaisa

AU - Yee, Karen K.

AU - Dalton, Pamela

AU - Ding, Xinxin

AU - Finel, Moshe

PY - 2009/12/1

Y1 - 2009/12/1

N2 - OBJECTIVES: Characterize the expression and glucuronidation activities of the human uridine 5′-diphospho (UDP)-glucuronosyltransferase (UGT) 2A2. METHOD: UGT2A1 was cloned from nasal mucosa mRNA. Synthetic cDNA for UGT2A2 was constructed assuming exon sharing between UGT2A1 and UGT2A2 (Mackenzie et al., Pharmacogenetics and Genomics 2005, 15:677-685). Exon 1 of UGT2A2 was amplified from genomic DNA and combined with exons 2-6 of UGT2A1. UGT2A3 was cloned from liver mRNA. Quantitative reverse-transcribed-PCR (RT-PCR) was used to evaluate the expression of all the three UGTs of subfamily 2A in different tissues. Recombinant UGT2A1, UGT2A2 and UGT2A3 were expressed in baculovirus-infected insect cells and analyzed for glucuronidation activity towards different substrates. RESULTS: DNA sequencing of RT-PCR products from human nasal mucosa mRNA, confirmed exon sharing between UGT2A1 and UGT2A2. In addition, it indicated that the N-terminal signal peptide sequence of UGT2A2 is the longest among the human UGTs. Quantitative RT-PCR revealed that both UGT2A1 and UGT2A2 are mainly expressed in the nasal mucosa, and that their expression level in fetal samples was much higher than in adults. Activity assays with recombinant UGTs 2A1-2A3 showed broad substrate selectivity for UGT2A1 and UGT2A2. Although glucuronidation rates and substrate affinities were mostly higher in UGT2A1, the Km values for UDP-glucuronic acid were similar in both UGTs. In addition, there were regioselectivity differences between the two UGTs and, with a few substrates, particularly ethinylestradiol, the activity of UGT2A2 was higher. CONCLUSION: UGT2A2 is mainly expressed in the nasal mucosa and it has glucuronidation activity towards several different endobiotic and xenobiotic substrates.

AB - OBJECTIVES: Characterize the expression and glucuronidation activities of the human uridine 5′-diphospho (UDP)-glucuronosyltransferase (UGT) 2A2. METHOD: UGT2A1 was cloned from nasal mucosa mRNA. Synthetic cDNA for UGT2A2 was constructed assuming exon sharing between UGT2A1 and UGT2A2 (Mackenzie et al., Pharmacogenetics and Genomics 2005, 15:677-685). Exon 1 of UGT2A2 was amplified from genomic DNA and combined with exons 2-6 of UGT2A1. UGT2A3 was cloned from liver mRNA. Quantitative reverse-transcribed-PCR (RT-PCR) was used to evaluate the expression of all the three UGTs of subfamily 2A in different tissues. Recombinant UGT2A1, UGT2A2 and UGT2A3 were expressed in baculovirus-infected insect cells and analyzed for glucuronidation activity towards different substrates. RESULTS: DNA sequencing of RT-PCR products from human nasal mucosa mRNA, confirmed exon sharing between UGT2A1 and UGT2A2. In addition, it indicated that the N-terminal signal peptide sequence of UGT2A2 is the longest among the human UGTs. Quantitative RT-PCR revealed that both UGT2A1 and UGT2A2 are mainly expressed in the nasal mucosa, and that their expression level in fetal samples was much higher than in adults. Activity assays with recombinant UGTs 2A1-2A3 showed broad substrate selectivity for UGT2A1 and UGT2A2. Although glucuronidation rates and substrate affinities were mostly higher in UGT2A1, the Km values for UDP-glucuronic acid were similar in both UGTs. In addition, there were regioselectivity differences between the two UGTs and, with a few substrates, particularly ethinylestradiol, the activity of UGT2A2 was higher. CONCLUSION: UGT2A2 is mainly expressed in the nasal mucosa and it has glucuronidation activity towards several different endobiotic and xenobiotic substrates.

KW - Glucuronidation

KW - Nasal mucosa mRNA

KW - Subfamily UGT2A

UR - http://www.scopus.com/inward/record.url?scp=73949103669&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73949103669&partnerID=8YFLogxK

U2 - 10.1097/FPC.0b013e3283330767

DO - 10.1097/FPC.0b013e3283330767

M3 - Article

C2 - 19858781

AN - SCOPUS:73949103669

VL - 19

SP - 923

EP - 934

JO - Pharmacogenetics and Genomics

JF - Pharmacogenetics and Genomics

SN - 1744-6872

IS - 12

ER -